SERPINA1 and alpha 1-antitrypsin deficiency: As a consequence, patients with AATD have low plasma AAT levels, resulting in a reduced ability to inhibit NE and leading to lung parenchymal destruction and the development of chronic obstructive pulmonary disease (COPD).